Cover Image
市場調查報告書

功能性(非潰瘍)消化不良 : 開發平台分析

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 251518
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
功能性(非潰瘍)消化不良 : 開發平台分析 Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2017
出版日期: 2017年07月11日 內容資訊: 英文 39 Pages
簡介

所謂非潰瘍消化不良是在表示原因不明的消化不良的前兆·症狀所用的用語。同時也被稱為機能性消化不良及非潰瘍胃痛。主要的前兆·症狀有下胸部和腹上部的灼熱感及不適(可靠用餐和製酸藥控制),飽脹感,打嗝,噁心等。易罹病素質有過量攝取咖啡因和酒精,抽煙,攝取特定藥物──部分OTC止痛藥(阿斯匹林,ibupurofen(advil,motrin及其它)),對胃有副作用的東西──等。主要治療藥有抗生素和抗憂鬱劑等。

本報告提供全球各國治療功能性(非潰瘍)消化不良所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

功能性(非潰瘍)消化不良概要

治療藥的開發

  • 功能性(非潰瘍)消化不良開發中產品:概要
  • 功能性(非潰瘍)消化不良開發中產品:比較分析

各企業開發中的功能性(非潰瘍)消化不良治療藥

大學/研究機關研究中的功能性(非潰瘍)消化不良治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

功能性(非潰瘍)消化不良治療藥:開發中的產品一覽(各企業)

功能性(非潰瘍)消化不良治療藥:研究中的產品一覽(大學/研究機關別)

功能性(非潰瘍)消化不良開發治療藥的企業

  • Almirall, S.A.
  • Eisai
  • Ironwood Pharmaceuticals, Inc.
  • RaQualia Pharma Inc.
  • Zensun (Shanghai) Sci & Tech Co., Ltd.
  • Zeria Pharmaceutical Co Ltd

功能性(非潰瘍)消化不良:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • acotiamide hydrochloride
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • cinitapride
  • IW-9179
  • rabeprazole sodium DR
  • RQ-00000010
  • RQ-00201894
  • Small Molecule to Activate 5-HT1 Receptor for Constipation and Dyspepsia
  • ZS-07

功能性(非潰瘍)消化不良治療藥:開發中產品的最新趨勢

功能性(非潰瘍)消化不良治療藥:開發暫停的產品

功能性(非潰瘍)消化不良治療藥:開發中止的產品

功能性(非潰瘍)消化不良相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9526IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2017, provides an overview of the Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline landscape.

Non-ulcer dyspepsia is a term used to describe signs and symptoms of indigestion that have no obvious cause. Non-ulcer dyspepsia is also called functional dyspepsia or non-ulcer stomach pain. Signs and symptoms include burning sensation or discomfort in your upper abdomen or lower chest, sometimes relieved by food or antacids, bloating, belching and nausea. The predisposing factors include consuming excessive amounts of caffeine or alcohol, smoking and taking certain medications, especially certain over-the-counter pain relievers, such as aspirin and ibuprofen (advil, motrin, others), which can cause stomach problems. Treatment includes medications to reduce acid production, antibiotics and low-dose antidepressants.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Functional (Non Ulcer) Dyspepsia (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Functional (Non Ulcer) Dyspepsia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Functional (Non Ulcer) Dyspepsia (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Functional (Non Ulcer) Dyspepsia (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Functional (Non Ulcer) Dyspepsia (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Functional (Non Ulcer) Dyspepsia (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Functional (Non Ulcer) Dyspepsia (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Functional (Non Ulcer) Dyspepsia (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Functional (Non Ulcer) Dyspepsia - Overview
    • Functional (Non Ulcer) Dyspepsia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Functional (Non Ulcer) Dyspepsia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Functional (Non Ulcer) Dyspepsia - Companies Involved in Therapeutics Development
    • Abide Therapeutics Inc
    • Daewoong Pharmaceutical Co Ltd
    • RaQualia Pharma Inc
    • Yuhan Corp
    • Zeria Pharmaceutical Co Ltd
  • Functional (Non Ulcer) Dyspepsia - Drug Profiles
    • 5-BIOP - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ABX-1431 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • acotiamide hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-4005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mosapride SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naronapride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RQ-00000010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RQ-00201894 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YH-12852 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Functional (Non Ulcer) Dyspepsia - Dormant Projects
  • Functional (Non Ulcer) Dyspepsia - Discontinued Products
  • Functional (Non Ulcer) Dyspepsia - Product Development Milestones
    • Featured News & Press Releases
      • Dec 14, 2016: Abide Therapeutics Announces First Patient Dosed in Phase 1b Study to Assess the Effect of ABX-1431 in Patients with Functional Dyspepsia
      • Mar 25, 2013: Zeria Pharma Receives Approval For Acofide In Japan For Treating Functional Dyspepsia
      • Feb 29, 2012: RaQualia Pharma Receives MHRA Approval To Initiate First-In-Human Study For 5-HT4 Partial Agonist RQ-00000010
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Functional (Non Ulcer) Dyspepsia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Functional (Non Ulcer) Dyspepsia - Pipeline by Abide Therapeutics Inc, H2 2017
  • Functional (Non Ulcer) Dyspepsia - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017
  • Functional (Non Ulcer) Dyspepsia - Pipeline by RaQualia Pharma Inc, H2 2017
  • Functional (Non Ulcer) Dyspepsia - Pipeline by Yuhan Corp, H2 2017
  • Functional (Non Ulcer) Dyspepsia - Pipeline by Zeria Pharmaceutical Co Ltd, H2 2017
  • Functional (Non Ulcer) Dyspepsia - Dormant Projects, H2 2017
  • Functional (Non Ulcer) Dyspepsia - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Functional (Non Ulcer) Dyspepsia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top